암 치료용 방사성 리간드 요법 시장

The global market for radioligand therapeutics in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.1% from 2025 through 2030.

The North American market for radioligand therapeutics in cancer treatment is estimated to grow from $2.1 billion in 2025 to $3.9 billion by the end of 2030, at a CAGR of 13.1% from 2025 through 2030.

The emerging regions’ market for radioligand therapeutics in cancer treatment is estimated to grow from $91.1 million in 2025 to $191.4 million by the end of 2030, at a CAGR of 16% from 2025 through 2030.

Report Scope

This report provides an in-depth analysis of the global market for radioligand therapeutics (RLT) in cancer treatment. It presents detailed market data for 2024 (base year), estimates for 2025 and forecasts with compound annual growth rates (CAGR) through 2030. The study evaluates current market dynamics, emerging trends and future growth potential driven by the adoption of prostate-specific membrane antigen (PSMA)- and somatostatin receptor (SSTR)-targeted therapies.

The report assesses the competitive environment, including product-level analysis of approved radioligand therapies such as 177Lu-vipivotide tetraxetan (Pluvicto) and 177Lu-dotatate (Lutathera), as well as pipeline assets targeting PSMA, SSTR, gastrin-releasing peptide receptor (GRPR) and other tumor-specific receptors. It also examines regulatory pathways and reimbursement frameworks.

Market segmentation encompasses product type, indication type, and end user, with additional assessments of drivers, restraints, opportunities, technological advances, and strategic activities such as collaborations, acquisitions, clinical trial investments, and expansion of isotope production capacity.

Segmental-level market data (by product type, indication type and end user) is limited to the North America region. This limitation highlights that the market for radioligand therapeutics in cancer treatment is centered in the U.S., where a single company's products (Pluvicto and Lutathera from Novartis AG) account for the majority of global sales and where reliable, detailed data are accessible. In other regions, RLT is still in an early stage, with limited commercial adoption and insufficient transparent data to enable detailed segment-level analysis.

Report Includes

• 15 data tables and 57 additional tables
• Overview and an analysis of the global markets for radioligand therapeutics (RLT) in cancer treatment
• Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on product type, disease indication, end user and region
• Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
• Highlights of promising new advancements in precision oncology, the emergence of innovative and effective theranostic agents, applications and potential
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Novartis AG, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Ltd., RayzeBio Inc., and Lilly USA LLC.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Current Market Scenario
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Geographical Factor
• Healthcare Spend
• Cancer Burden and Demographics
• Reimbursement and Funding Climate
• Impact of U.S. Tariffs on Radioligand Therapeutics in Cancer Treatment Supply Chains
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Cancer Incidence and Population Aging
• Increasing Approvals and Label Expansions of Radioligand Therapeutics Products
• Centers for Medicare and Medicaid Services (CMS) Separate Payment for Therapeutic Radiopharmaceuticals
• Market Restraints/Challenges
• Therapeutic Isotope Supply Constraints
• Nuclear Medicine and Radiopharmacy Workforce Shortage
• Growing Competition from Alternative Modalities such as Antibody-Drug Conjugates (ADCs)
• Market Opportunities
• Development of Alpha-Emitter Therapies and Novel Targets
• Earlier-Line Use and Combination Regimens with Standard of Care
• Increasing R&D Investments and Strategic Alliances

Chapter 4 Regulatory Landscape

• Overview
• Regulatory Frameworks by Country/Region
• U.S.
• Canada
• Europe
• Emerging Markets

Chapter 5 Emerging Technologies and Developments

• Key Takeaways
• Targeted Alpha Therapies (TATs)
• Next-Generation Isotopes and Smarter Ligands
• Personalized, Dosimetry-Guided RLT (AI-Assisted)

Chapter 6 Pipeline and Clinical Analysis

• Key Takeaways
• Pipeline Analysis
• Clinical Trials Analysis
• Key Takeaways
• Clinical Trial Studies on Radioligand Therapeutics in Cancer Treatment

Chapter 7 Patent Analysis

• Key Takeaways
• Patent Analysis
• Recent Patent Grants

Chapter 8 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Radioligand Therapeutics in Cancer Treatment, by Product Type
• Key Takeaways
• Lutetium-177 Dotatate
• Others (Pipeline)
• Global Market for Radioligand Therapeutics in Cancer Treatment, by Indication
• Key Takeaways
• Prostate Cancer
• Neuroendocrine Tumors
• Others (Pipeline)
• Global Market for Radioligand Therapeutics in Cancer Treatment, by End User
• Key Takeaways
• Academic/Comprehensive Cancer Centers
• Hospital-Based Nuclear Medicine
• Specialized Private Nuclear Medicine Clinics
• Geographic Breakdown
• Global Market for Radioligand Therapeutics in Cancer Treatment, by Region
• Key Takeaways
• North America
• Europe
• Emerging Markets

Chapter 9 Competitive Intelligence

• Competitive Landscape
• Key Takeaways
• Novartis AG RLT Sales, 2024
• Other Competitors in the Pipeline

Chapter 10 Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment: An ESG Perspective

• Introduction to ESG
• Sustainability in the Global Market for Radioligand Therapeutics in Cancer Treatment
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 11 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABDERA THERAPEUTICS
• ARICEUM THERAPEUTICS
• CLARITY PHARMACEUTICALS
• CONVERGENT THERAPEUTICS INC.
• CURIUM
• FUSION PHARMA
• ITM ISOTOPE TECHNOLOGIES MUNICH SE
• LILLY USA LLC.
• NOVARTIS AG
• ORANO MED
• PERSPECTIVE THERAPEUTICS
• PRECIRIX
• RADIOPHARM THERANOSTICS LTD.
• RAYZEBIO INC.
• TELIX PHARMACEUTICALS LTD.
• Few Emerging Companies in the Global Market for Radioligand Therapeutics in Cancer Treatment